Bispecific antibodies that bind to CD38 and CD3
The invention provides novel heterodimeric proteins including heterodimeric antibodies.
1. A heterodimeric antibody comprising:
a) a first heavy chain comprising:
i) a first Fc domain variant;
ii) a single chain Fv region (scFv) that binds CD3; and
b) a second heavy chain comprising:
i) a second Fc domain variant; and
ii) a first variable heavy domain; and
c) a first light chain comprising a first variable light domain and a first constant light domain; wherein said first variable heavy domain and said first variable light domain bind to CD38 and comprise CDR sequences selected from the group consisting of
(a) first variable heavy domain CDR sequences RSWMN (SEQ ID NO: 541), EINPDSSTINYATSVKG (SEQ ID NO: 542), and YGNWFPY (SEQ ID NO: 543) and first variable light domain CDR sequences RASQNVDTWVA (SEQ ID NO: 544), SASYRYS (SEQ ID NO: 545), and QQYDSYPLT (SEQ ID NO: 546);
(b) first variable heavy domain CDR sequences RSWMN (SEQ ID NO: 541), EINPDSSTINYATSVKG (SEQ ID NO: 542), and YGNWFPY(SEQ ID NO: 543) and first variable light domain CDR sequences RASQNVDTNVA (SEQ ID NO: 547), SASYRYS (SEQ ID NO: 545), and QQYDSYPLT (SEQ ID NO: 546);
(c) first variable heavy domain CDR sequences RSWMN (SEQ ID NO: 541), EINPDSSTINYATSVKG (SEQ ID NO: 542), and YGNWFPY (SEQ ID NO: 543) and first variable light domain CDR sequences RASQNVDYWVA (SEQ ID NO: 548), AASWRYS (SEQ ID NO: 549), and QQYDVYPLT (SEQ ID NO: 550);
(d) first variable heavy domain CDR sequences YSWMN (SEQ ID NO: 551), EINPQSSTINYATSVKG (SEQ ID NO: 552), and YGNWFPY (SEQ ID NO: 543) and first variable light domain CDR sequences RASQNVDYWVA (SEQ ID NO: 548), AASWRYS (SEQ ID NO: 549), and QQYDVYPLT (SEQ ID NO: 550);
(e) first variable heavy domain CDR sequences YSWMN (SEQ ID NO: 551), EINPQSSTINYATSVKG (SEQ ID NO: 552), and YGNWFPY (SEQ ID NO: 543) and first variable light domain CDR sequences RASQNVDYWVA (SEQ ID NO: 548), SASWRYS (SEQ ID NO: 553), and QQYDVYPLT (SEQ ID NO: 550);
(f) first variable heavy domain CDR sequences YSWMN (SEQ ID NO: 551), EINPQSSTINYATSVKG (SEQ ID NO: 552), and YGNWFPY (SEQ ID NO: 543) and first variable light domain CDR sequences RASQNVDYWVA (SEQ ID NO: 548), SASWRYS (SEQ ID NO: 553), and QQYDVYPLT (SEQ ID NO: 550);
(g) first variable heavy domain CDR sequences RSWMN (SEQ ID NO: 541), EINPQSSTINYATSVKG (SEQ ID NO: 552), and YGNWFPY (SEQ ID NO: 543) and first variable light domain CDR sequences RASQNVDYWVA (SEQ ID NO: 548), AASWRYS (SEQ ID NO: 549), and QQYDVYPLT (SEQ ID NO: 550); and
(h) first variable heavy domain CDR sequences YSWMN (SEQ ID NO: 551), EINPQSSTINYATSVKG (SEQ ID NO: 552), and YGNWFPY (SEQ ID NO: 543) and first variable light domain CDR sequences RASQNVDTWVA (SEQ ID NO: 544), SASYRYS (SEQ ID NO: 545), and QQYDSYPLT (SEQ ID NO: 546).
2. The heterodimeric antibody according to claim 1 , wherein the first variable heavy domain comprises CDR sequences RSWMN (SEQ ID NO: 541), EINPDSSTINYATSVKG (SEQ ID NO: 542), and YGNWFPY (SEQ ID NO: 543) and the first variable light domain comprises CDR sequences RASQNVDTWVA (SEQ ID NO: 544), SASYRYS (SEQ ID NO: 545), and QQYDSYPLT (SEQ ID NO: 546).
3. The heterodimeric antibody according to claim 1 wherein said scFv has a charged scFv linker.
4. The heterodimeric antibody according to claim 3 wherein charged scFv linker has a positive charge from 3 to 8 and is selected from the group consisting of SEQ ID NO:s 443 to 451.
5. A pharmaceutical composition comprising the heterodimeric antibody of claim 1 .
6. The heterodimeric antibody of claim 1 , wherein the first heavy chain comprises the Fc domain of SEQ ID NO: 520.
7. The heterodimeric antibody of claim 1 , wherein the first heavy chain comprises amino acids 255-485 of SEQ ID NO: 520.
8. The heterodimeric antibody of claim 2 , wherein the first heavy chain comprises the Fc domain of SEQ ID NO: 520.
9. The heterodimeric antibody of claim 2 , wherein the first heavy chain comprises amino acids 255-485 of SEQ ID NO: 520.
10. The heterodimeric antibody of claim 3 , wherein the first heavy chain comprises the Fc domain of SEQ ID NO: 520.
11. The heterodimeric antibody of claim 3 , wherein the first heavy chain comprises amino acids 255-485 of SEQ ID NO: 520.
12. The heterodimeric antibody of claim 4 , wherein the first heavy chain comprises the Fc domain of SEQ ID NO: 520.
13. The heterodimeric antibody of claim 4 , wherein the first heavy chain comprises amino acids 255-485 of SEQ ID NO: 520.
14. A nucleic acid composition comprising:
a) a first nucleic acid encoding the first heavy chain of claim 1 ;
b) a second nucleic acid encoding the second heavy chain of claim 1 ; and
c) a third nucleic acid encoding said light chain.
15. A nucleic acid composition comprising:
a) a first expression vector comprising a first nucleic acid encoding the first heavy chain of claim 1 ;
b) a second expression vector comprising a second nucleic acid encoding the second heavy chain of claim 1 ; and
c) a third expression vector comprising a third nucleic acid encoding said light chain.
16. A host cell comprising the nucleic acid composition of claim 14 .
17. A host cell comprising the nucleic acid comprising of claim 15 .
18. A method of producing a heterodimeric antibody according claim 1 comprising:
a) providing a first expression vector comprising a first nucleic acid encoding a first heavy chain comprising:
i) a first Fc domain; and
ii) a first variable heavy chain; and
b) providing a second expression vector comprising a second nucleic acid encoding a second heavy chain comprising:
i) a first Fc domain; and
ii) a single chain Fv region (scFv) that binds CD3; and
c) providing a third expression vector comprising nucleic acid comprising a light chain; wherein said first variable heavy chain and the variable light domain of said light chain bind CD38;
d) wherein said first, second and third expression vectors are transfected into host cells at a ratio selected from the group consisting of 1:1.5:1.5, 1:2:1.5, 1:0.667:2, 1:1:2, 1:1.5:2, and 1:2:2;
e) expressing said first, second and third nucleic acids in said host cells to produce a first, second and third amino acid sequence, respectively, such that said first, second and third amino acid sequences form said heterodimeric antibody.
19. The method of claim 18 , further comprising (f) formulating the heterodimeric antibody into a pharmaceutical composition.
20. A method of treating a patient in need thereof by administering a heterodimeric antibody according to claim 1 .